The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository

Background: Genetic, biologic and clinical data suggest that Parkinson’s disease (PD) is an umbrella for multiple disorders with clinical and pathological overlap, yet with different underlying mechanisms. To better understand these and to move towards neuroprotective treatment, we have established the Quebec Parkinson Network (QPN), an open-access patient registry, and data and bio-samples repository. Objective: To present the QPN and to perform preliminary analysis of the QPN data. Methods: A total of 1,070 consecutively recruited PD patients were included in the analysis. Demographic and clinical data were analyzed, including comparisons between males and females, PD patients with and without RBD, and stratified analyses comparing early and late-onset PD and different age groups. Results: QPN patients exhibit a male:female ratio of 1.8:1, an average age-at-onset of 58.6 years, an age-at-diagnosis of 60.4 years, and average disease duration of 8.9 years. REM-sleep behavior disorder (RBD) was more common among men, and RBD was associated with other motor and non-motor symptoms including dyskinesia, fluctuations, postural hypotension and hallucinations. Older patients had significantly higher rates of constipation and cognitive impairment, and longer disease duration was associated with higher rates of dyskinesia, fluctuations, freezing of gait, falls, hallucinations and cognitive impairment. Since QPN’s creation, over 60 studies and 30 publications have included patients and data from the QPN. Conclusions: The QPN cohort displays typical PD demographics and clinical features. These data are open-access upon application (http://rpq-qpn.ca/en/), and will soon include genetic, imaging and bio-samples. We encourage clinicians and researchers to perform studies using these resources.

[1]  A. Strafella,et al.  Transcranial magnetic stimulation improves cognition over time in Parkinson's disease. , 2019, Parkinsonism & related disorders.

[2]  D. Hernandez,et al.  Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset , 2019, npj Parkinson's Disease.

[3]  Sonja W. Scholz,et al.  Parkinson's disease age at onset genome‐wide association study: Defining heritability, genetic loci, and α‐synuclein mechanisms , 2019, Movement disorders : official journal of the Movement Disorder Society.

[4]  W. Chung,et al.  SMPD1 mutations, activity, and α‐synuclein accumulation in Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[5]  O. Monchi,et al.  Common and rare GCH1 variants are associated with Parkinson's disease , 2019, Neurobiology of Aging.

[6]  Sonja W. Scholz,et al.  Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease , 2018, JAMA neurology.

[7]  A. Singleton,et al.  Finding useful biomarkers for Parkinson’s disease , 2018, Science Translational Medicine.

[8]  R. Barker,et al.  Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  W. Oertel,et al.  LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. , 2018, Parkinsonism & related disorders.

[10]  R. Postuma,et al.  The GBA p.Trp378Gly mutation is a probable French‐Canadian founder mutation causing Gaucher disease and synucleinopathies , 2018, Clinical genetics.

[11]  E. Bézard,et al.  Cardinal Motor Features of Parkinson’s Disease Coexist with Peak-Dose Choreic-Type Drug-Induced Dyskinesia , 2018, Journal of Parkinson's disease.

[12]  A. Desautels,et al.  Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder , 2018, Movement disorders : official journal of the Movement Disorder Society.

[13]  J. Cedarbaum,et al.  Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic , 2018, Movement disorders : official journal of the Movement Disorder Society.

[14]  K. Marder,et al.  Progression in the LRRK2-Asssociated Parkinson Disease Population , 2018, JAMA neurology.

[15]  N. Dupré,et al.  The influence of vascular risk factors on cognitive function in early Parkinson's disease , 2018, International journal of geriatric psychiatry.

[16]  Réjean Plamondon,et al.  Cranio-Caudal Kinematic Turn Signature Assessed with Inertial Systems As a Marker of Mobility Deficits in Parkinson’s Disease , 2018, Front. Neurol..

[17]  Sonja W. Scholz,et al.  Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease , 2017, Neurobiology of Aging.

[18]  Patrick Boissy,et al.  Using Inertial Sensors to Automatically Detect and Segment Activities of Daily Living in People With Parkinson’s Disease , 2018, IEEE Transactions on Neural Systems and Rehabilitation Engineering.

[19]  G. Rouleau,et al.  The Tanenbaum Open Science Institute: Leading a Paradigm Shift at the Montreal Neurological Institute , 2017, Neuron.

[20]  Jean-François Gagnon,et al.  REM Sleep Behavior Disorder and Cognitive Impairment in Parkinson's Disease , 2017, Sleep.

[21]  A. Dagher,et al.  Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.

[22]  Y. Dauvilliers,et al.  RIC3 variants are not associated with Parkinson's disease in French-Canadians and French , 2017, Neurobiology of Aging.

[23]  Patrick Boissy,et al.  Auto detection and segmentation of daily living activities during a Timed Up and Go task in people with Parkinson’s disease using multiple inertial sensors , 2017, Journal of NeuroEngineering and Rehabilitation.

[24]  R. Alcalay,et al.  Genetic Forms of Parkinson's Disease , 2017, Seminars in Neurology.

[25]  N. Dupré,et al.  Smoking history is associated to cognitive impairment in Parkinson's disease , 2017, Aging & mental health.

[26]  O. Monchi,et al.  Depressive symptoms in Parkinson’s disease correlate with cortical atrophy over time , 2017, Brain and Cognition.

[27]  D. Louis Collins,et al.  Cyberinfrastructure for Open Science at the Montreal Neurological Institute , 2017, Front. Neuroinform..

[28]  D. Holtzman,et al.  Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. , 2017, The journal of prevention of Alzheimer's disease.

[29]  R. Postuma,et al.  Dementia Predictors in Parkinson Disease: A Validation Study. , 2017, Journal of Parkinson's disease.

[30]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[31]  C. Mariani,et al.  Survival and dementia in GBA‐associated Parkinson's disease: The mutation matters , 2016, Annals of neurology.

[32]  Tristan Glatard,et al.  The MNI data-sharing and processing ecosystem , 2016, NeuroImage.

[33]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[34]  Jean-François Gagnon,et al.  New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.

[35]  B. Wang,et al.  Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease , 2015, Molecular medicine.

[36]  K. Marder,et al.  Differential effects of severe vs mild GBA mutations on Parkinson disease , 2015, Neurology.

[37]  O. Monchi,et al.  Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson’s Disease , 2014, Front. Neurol..

[38]  T. Dall,et al.  The current and projected economic burden of Parkinson's disease in the United States , 2013, Movement disorders : official journal of the Movement Disorder Society.

[39]  Poul Jennum,et al.  A single‐question screen for rapid eye movement sleep behavior disorder: A multicenter validation study , 2012, Movement disorders : official journal of the Movement Disorder Society.

[40]  Alan C. Evans,et al.  LORIS: a web-based data management system for multi-center studies , 2012, Front. Neuroinform..

[41]  D. Aarsland,et al.  Nonlinear decline of mini‐mental state examination in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[42]  M. Vidailhet,et al.  Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. , 2011, Human molecular genetics.

[43]  A. Mirelman,et al.  LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease , 2010, neurogenetics.

[44]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[45]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[46]  Enrico Marchioni,et al.  Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease , 2005, Movement disorders : official journal of the Movement Disorder Society.

[47]  Tore Wentzel-Larsen,et al.  The rate of cognitive decline in Parkinson disease. , 2004, Archives of neurology.

[48]  M. Onofrj,et al.  Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up , 2002, Neurological Sciences.